Empagliflozin 25 mg + Sitagliptin 100 mg: Uses, Benefits & Precautions
GLIEMPAFLOZIN SITA 25/100 contains Empagliflozin 25 mg and Sitagliptin 100 mg and is marketed by Steris Healthcare. This prescription combination is used as part of a comprehensive treatment plan for type 2 diabetes mellitus when appropriate. Empagliflozin and sitagliptin work through different mechanisms to improve blood-glucose control, making the combination useful for selected patients whose diabetes requires more than one therapeutic approach.
What is Empagliflozin 25 mg, Sitagliptin 100 mg Used For?
GLIEMPAFLOZIN SITA 25/100 is used to help control elevated blood glucose in adults with type 2 diabetes mellitus, alongside an appropriate diet and regular physical activity.
Empagliflozin belongs to the SGLT2 inhibitor class, while sitagliptin is a DPP-4 inhibitor. The two medicines target different pathways involved in glucose regulation.
This combination is not intended to treat type 1 diabetes or diabetic ketoacidosis. Treatment should be individualized according to blood-glucose levels, kidney function, cardiovascular status and other medicines.
Why is Empagliflozin 25 mg, Sitagliptin 100 mg Important?
Type 2 diabetes involves complex abnormalities in glucose regulation, including insulin resistance, impaired insulin secretion and excessive glucose production.
Using medicines with complementary mechanisms can provide a broader approach to glucose management. Empagliflozin promotes urinary glucose excretion, while sitagliptin enhances the body's incretin response, helping regulate glucose-dependent insulin secretion.
Good diabetes management also includes nutrition, physical activity, regular monitoring and appropriate medical follow-up.
Key Benefits
What are the Benefits?
When appropriately prescribed, the combination may:
- Help reduce elevated blood glucose.
- Improve overall glycemic control in adults with type 2 diabetes.
- Provide complementary glucose-lowering effects through two different mechanisms.
- Empagliflozin may promote urinary glucose elimination.
- Sitagliptin supports glucose-dependent insulin release.
- Sitagliptin can help reduce inappropriate glucagon secretion after meals.
- Empagliflozin may provide additional cardiovascular and kidney-related benefits in certain appropriately selected patients.
The degree of benefit depends on the individual's diabetes control, kidney function, adherence and overall treatment plan.
Side Effects
Possible side effects may include:
- Increased urination
- Increased thirst
- Genital fungal infections
- Urinary tract infections
- Nausea
- Headache
- Gastrointestinal discomfort
- Mild dehydration
- Nasopharyngitis or cold-like symptoms
Low blood sugar can occur, particularly when this combination is used with insulin or insulin-secretagogue medicines such as sulfonylureas.
Serious Side Effects
Seek prompt medical attention for:
- Symptoms of diabetic ketoacidosis, including nausea, vomiting, abdominal pain, unusual tiredness or difficulty breathing
- Severe dehydration or fainting
- Serious urinary or genital infection
- Severe allergic reaction
- Facial, lip or throat swelling
- Persistent severe abdominal symptoms
- Symptoms of pancreatitis, such as persistent severe abdominal pain
Empagliflozin can increase the risk of ketoacidosis in certain circumstances, sometimes even when blood glucose is not extremely high.
Available Substitute
There is no single substitute suitable for every patient.
Depending on the individual's diabetes status, a healthcare professional may consider other combinations involving:
- Empagliflozin with another glucose-lowering medicine
- Sitagliptin with another antidiabetic medicine
- Metformin-based combinations
- Other SGLT2 inhibitors
- Other DPP-4 inhibitors
- GLP-1 receptor agonists
- Insulin therapy when clinically indicated
The appropriate alternative depends on HbA1c, kidney function, cardiovascular risk, weight considerations, hypoglycemia risk and other medicines.
Dosage Guidelines
Take GLIEMPAFLOZIN SITA 25/100 only according to the dosage prescribed by your healthcare professional.
The recommended regimen depends on the patient's previous diabetes therapy and kidney function. Kidney function is particularly important because both components have renal considerations.
Important points include:
- Take the medicine exactly as prescribed.
- Maintain adequate fluid intake unless your doctor has advised fluid restriction.
- Do not double the dose after a missed dose.
- Monitor blood glucose as recommended.
- Continue prescribed dietary and exercise measures.
- Do not stop diabetes treatment without medical advice.
Precautions & Warnings
Before using Empagliflozin 25 mg, Sitagliptin 100 mg, inform your healthcare professional if you have:
- Kidney disease
- Recurrent urinary or genital infections
- Low blood pressure or dehydration
- Pancreatitis or a history of pancreatitis
- A history of diabetic ketoacidosis
- Heart failure or cardiovascular disease
- A planned surgical procedure
- A restricted-fluid diet
- Other diabetes medicines
Empagliflozin may increase urination and fluid loss. Patients at risk of dehydration or low blood pressure should be monitored carefully.
Mechanism of Action
Empagliflozin
Empagliflozin is an SGLT2 inhibitor. SGLT2 proteins normally help reabsorb glucose from the kidney back into the bloodstream.
Empagliflozin inhibits SGLT2, reducing renal glucose reabsorption and increasing urinary glucose excretion. This lowers blood glucose and can also produce mild osmotic diuresis and natriuresis.
Sitagliptin
Sitagliptin is a DPP-4 inhibitor. DPP-4 normally breaks down incretin hormones such as GLP-1 and GIP.
By inhibiting DPP-4, sitagliptin increases the activity of these hormones. This enhances glucose-dependent insulin secretion and decreases glucagon secretion when blood glucose is elevated.
Combined Action
The two components therefore lower glucose through complementary pathways:
- Empagliflozin: increases urinary glucose elimination.
- Sitagliptin: enhances glucose-dependent insulin response and reduces excessive glucagon activity.
This complementary action can provide effective glycemic control for appropriately selected adults with type 2 diabetes.
Conclusion
GLIEMPAFLOZIN SITA 25/100, containing Empagliflozin 25 mg and Sitagliptin 100 mg and marketed by Steris Healthcare, is a prescription combination designed to improve blood-glucose control in adults with type 2 diabetes mellitus.
Empagliflozin works primarily through SGLT2 inhibition, increasing urinary glucose excretion, while sitagliptin works through DPP-4 inhibition, strengthening the body's incretin-mediated glucose response. Together, they provide complementary glucose-lowering effects.
Treatment should be individualized according to kidney function, diabetes control, cardiovascular status and concurrent medicines. Patients should remain alert for dehydration, genital or urinary infections and symptoms suggestive of diabetic ketoacidosis or pancreatitis.
Comments
Post a Comment